Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 19 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-8.69 Insider Own0.18% Shs Outstand5.89M Perf Week-6.48%
Market Cap38.23M Forward P/E- EPS next Y-4.58 Insider Trans0.00% Shs Float5.88M Perf Month-16.79%
Income-47.73M PEG- EPS next Q-1.79 Inst Own36.52% Short Float0.65% Perf Quarter-57.36%
Sales9.81M P/S3.90 EPS this Y31.36% Inst Trans-73.54% Short Ratio1.36 Perf Half Y-46.98%
Book/sh1.61 P/B4.04 EPS next Y25.56% ROA-60.97% Short Interest0.04M Perf Year-60.62%
Cash/sh6.91 P/C0.94 EPS next 5Y- ROE-207.29% 52W Range3.80 - 17.49 Perf YTD-49.10%
Dividend Est.- P/FCF- EPS past 5Y14.56% ROI-94.10% 52W High-62.89% Beta3.36
Dividend TTM- Quick Ratio4.08 Sales past 5Y-0.68% Gross Margin87.95% 52W Low70.79% ATR (14)0.53
Dividend Ex-Date- Current Ratio4.08 EPS Y/Y TTM21.44% Oper. Margin-501.16% RSI (14)29.22 Volatility5.60% 6.96%
Employees49 Debt/Eq4.50 Sales Y/Y TTM-5.67% Profit Margin-486.45% Recom1.33 Target Price22.50
Option/ShortNo / Yes LT Debt/Eq4.36 EPS Q/Q14.18% Payout- Rel Volume0.00 Prev Close6.49
Sales Surprise4.24% EPS Surprise-0.41% Sales Q/Q-9.19% EarningsMay 07 BMO Avg Volume28.32K Price6.49
SMA20-6.62% SMA50-30.56% SMA200-36.08% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Nov-17-23Initiated Truist Buy $26
Apr-04-22Downgrade Raymond James Outperform → Mkt Perform
Oct-13-21Initiated Raymond James Outperform $15
Mar-25-21Initiated B. Riley Securities Buy $19
Jul-29-20Initiated Laidlaw Buy $5
Jul-17-20Initiated Cantor Fitzgerald Overweight $4
Oct-24-17Initiated Guggenheim Buy $7
Mar-02-16Initiated Sun Trust Rbsn Humphrey Buy $3
Nov-09-15Reiterated ROTH Capital Buy $6 → $5
Aug-11-15Initiated FBR Capital Outperform $6
Jul-10-24 07:30AM
Jul-09-24 12:00PM
Jul-08-24 07:30AM
May-14-24 04:00PM
May-10-24 08:00AM
11:39AM Loading…
May-08-24 11:39AM
May-07-24 12:53PM
Apr-30-24 08:00AM
Apr-05-24 08:43AM
Apr-04-24 07:30AM
Feb-09-24 10:10AM
Feb-08-24 08:11AM
08:00AM Loading…
Feb-01-24 08:00AM
Jan-05-24 08:00AM
Dec-12-23 08:00AM
Dec-11-23 08:00AM
Dec-06-23 08:00AM
Dec-05-23 08:00AM
Nov-03-23 10:26AM
Nov-02-23 08:19AM
Oct-30-23 10:00AM
Oct-26-23 08:30AM
Oct-06-23 08:56AM
Sep-22-23 03:15AM
08:00AM Loading…
Sep-12-23 08:00AM
Sep-06-23 08:13AM
Aug-05-23 05:57AM
Aug-03-23 05:45PM
Jul-27-23 06:25PM
Jul-06-23 08:01AM
Jun-30-23 06:50AM
Jun-06-23 06:54AM
May-15-23 11:33AM
May-05-23 07:30AM
May-04-23 05:45PM
Apr-27-23 04:01PM
Apr-17-23 08:12AM
Apr-05-23 08:13PM
Apr-03-23 08:00AM
Mar-14-23 11:02AM
Mar-13-23 10:21PM
Mar-08-23 07:09PM
Mar-02-23 04:01PM
Jan-20-23 10:09AM
Dec-12-22 10:00AM
Dec-05-22 11:08PM
Nov-12-22 07:43AM
Nov-10-22 02:30PM
Nov-09-22 05:45PM
Nov-07-22 04:01PM
Nov-02-22 04:00PM
Oct-07-22 04:01PM
Oct-03-22 04:01PM
Sep-19-22 09:16PM
Sep-07-22 08:00AM
Aug-31-22 12:53PM
Aug-30-22 08:52AM
Aug-19-22 12:25PM
Aug-18-22 08:49AM
Aug-13-22 10:05AM
Aug-05-22 03:30AM
Aug-04-22 06:25PM
Jul-29-22 04:00PM
Jul-28-22 04:00PM
Jul-08-22 07:56AM
Jul-07-22 04:01PM
Jun-10-22 07:00AM
Jun-06-22 07:48AM
Jun-04-22 09:00AM
Jun-02-22 08:00AM
May-12-22 10:26AM
May-11-22 08:59AM
May-06-22 01:01AM
May-05-22 06:05PM
May-04-22 09:35AM
Apr-28-22 04:00PM
Apr-21-22 07:28AM
Apr-12-22 11:57AM
Apr-11-22 08:00AM
Apr-07-22 04:01PM
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.